Has Lindsay Strowd, MD received payments from drug or device companies?

Yes. Drug and device makers reported $51,129 in general payments to Lindsay Strowd, MD across 38 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lindsay Strowd, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lindsay Strowd, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lindsay Strowd, MD

Dermatology · Reisterstown, MDNPI 1255567269

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $35,746 of the $51,129 with a category attached, or 69.9%. 8 manufacturers reported payments, led by Johnson & Johnson at 26.3% of the total. Reporting peaked in 2019 at $22,531 and has fallen 62.7% since, to $8,400 in 2025. Among dermatology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,129in general payments, 2019–2025

Across 38 payments — averaging $1345.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$13K
Galderma Laboratories, L.p.$13K
Eli Lilly$8K
Incyte Corporation$8K
Helsinn Therapeutics (U.S.), Inc.$6K
Sanofi$2K
plus $62 from 2 others

$177,465in research payments, 2019–2025

Across 27 payments — averaging $6572.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$95K
Pfizer$60K
Eli Lilly$12K
Regeneron$10K

What the payments were for

Consulting fees$35,74670%
Speaking & faculty fees$6,15012%
Grants$6,00012%
Travel & lodging$2,4615%
Food & beverage$6571%
Education$1140%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	18	$13,432
Galderma Laboratories, L.p.	5	$13,148
Eli Lilly	2	$8,400
Incyte Corporation	7	$8,160
Helsinn Therapeutics (U.S.), Inc.	3	$6,242
Sanofi	1	$1,686
UCB, Inc.	1	$47
Bausch Health US, LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$13,042
EBGLYSS$8,400
VALCHLOR$1,845
AKLIEF$1,748
DUPIXENT$1,686
ORACEA$113

How this compares

$51,129 in reported general payments places this provider in the 90th percentile of 306 dermatology providers in Maryland.

See all dermatology providers in Maryland →

Medicare billing

Part B allowed, 2024

$56,965

Medicare patients

459

Services billed

931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	90	$329,491
Humira(Cf) PenAdalimumab	12	$151,986
Dupixent SyringeDupilumab	27	$103,687
PegasysPeginterferon Alfa-2a	12	$53,721
Bexarotene	19	$44,810
AdbryTralokinumab-Ldrm	11	$44,227
Pimecrolimus	16	$5,401
Clobetasol Propionate	97	$4,031
Fluorouracil	21	$1,504
Tretinoin	23	$1,461
MethotrexateMethotrexate Sodium	66	$1,436
Fluocinonide	21	$1,309
Doxycycline Hyclate	54	$1,306
Triamcinolone Acetonide	81	$1,264
Mycophenolate Mofetil	18	$1,046

Paid to pharmacies, not to this prescriber.

Other dermatology in Reisterstown

Benjamin LockshinSilver Spring$4M
Shawn KwatraBaltimore$1.1M
Chesahna Kindred WeaverMarriottsville$837K
Oanh LauringNottingham$763K
Ronald PrussickN Bethesda$620K
Rebecca KazinChevy Chase$342K
Susan WalkerBethesda$221K
Monte MeltzerBerlin$220K
Valerie CallenderGlenn Dale$183K
David StrobelCatonsville$180K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →